Immunogenicity to biotherapeutics - The role of anti-drug immune complexes

Frontiers in Immunology

Volumn 7, Issue FEB, 2016, Pages

  Krishna, Murli ^a   Nadler, Steven G ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Biotherapeutics; Hypersensitivity; Immune complexes; Immunogenicity; Immunogenicity assay; Immunogenicity prediction; Neutralizing antibodies; Risk assessment

Indexed keywords

ADALIMUMAB; B CELL MATURATION ANTIGEN; B LYMPHOCYTE RECEPTOR; DRUG ANTIBODY; ETANERCEPT; FC RECEPTOR; GAMMA INTERFERON; INFLIXIMAB; NEUTRALIZING ANTIBODY;

ADAPTIVE IMMUNITY; ALLERGIC REACTION; ANAPHYLAXIS; ANTIGEN ANTIBODY COMPLEX; CELL MIGRATION; CELL SPECIFICITY; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; CROSS LINKING; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOTOXICITY; PROTEIN ANALYSIS; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE ACTIVATION; THROMBOEMBOLISM;

EID: 84962582891     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00021     Document Type: Review

References (87)

1. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol (2013) 9:164-72. doi:10.1038/nrrheum.2013.4.
2. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov (2008) 7(1):21-39. doi:10.1038/nrd2399.
3. Deehan M, Garces S, Kramer D, Baker MP, Rat D, Roettger Y, et al. Managing unwanted immunogenicity of biologicals. Autoimmun Rev (2015) 14:569-74. doi:10.1016/j.autrev.2015.02.007.
4. Schellekens H. The immunogenicity of therapeutic proteins. Discov Med (2010) 9(49):560-4.
5. Leach MW, Rottman JB, Hock MB, Finco D, Rojko JL, Beyer JC. Immunogenicity/hypersensitivity of biologics. Toxicol Pathol (2014) 42(1):293-300. doi:10.1177/0192623313510987.
6. Sethu S, Govindappa K, Alhaidari M, Pirmohamed M, Park K, Sathish J. Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp (Warsz) (2012) 60(5):331-44. doi:10.1007/s00005-012-0189-7.
7. Büttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher A, Jefferis R, et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals (2011) 39(2):100-9. doi:10.1016/j.biologicals.2011.01.006.
8. Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods (2008) 333(1-2):1-9. doi:10.1016/j.jim.2008.01.001.
9. Kloks C, Berger C, Cortez P, Dean Y, Heinrich J, Bjerring Jensen L, et al. A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective. J Immunol Methods (2015) 417:1-9. doi:10.1016/j.jim.2015.01.003.
10. Goins CL, Chappell CP, Shashidharamurthy R, Selvaraj P, Jacob J. Immune complex-mediated enhancement of secondary antibody responses. J Immunol (2010) 184(11):6293-8. doi:10.4049/jimmunol.0902530.
11. Mark Hogarth P. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol (2002) 14:798-802. doi:10.1016/S0952-7915(02)00409-0.
12. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol (2010) 10(5):328-43. doi:10.1038/nri2762.
13. Mayadas TN, Tsokos GC, Tsuboi N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation (2009) 120(20):2012-24. doi:10.1161/CIRCULATIONAHA.108.771170.
14. Carroll MC. The complement system in B cell regulation. Mol Immunol (2004) 41(2-3):141-6. doi:10.1016/j.molimm.2004.03.017.
15. Chauhan AK, Moore TL. Immune complexes and late complement proteins trigger activation of Syk tyrosine kinase in human CD4 (+) T cells. Clin Exp Immunol (2012) 167(2):235-45. doi:10.1111/j.1365-2249.2011.04505.x.
16. Fogdell-Hahn A. Antidrug antibodies: B cell immunity against therapy. Scand J Immunol (2015) 82(3):184-90. doi:10.1111/sji.12327.
17. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol (2005) 5(11):853-65. doi:10.1038/nri1714.
18. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol (2002) 14:129-35. doi:10.1016/S0952-7915(01)00308-9.
19. Chauhan AK, Chen C, Moore TL, DiPaolo RJ. Induced expression of FcRIIIa (CD16a) on CD4 T cells triggers generation of IFN-γ high subset. J Biol Chem (2015) 290(8):5127-40. doi:10.1074/jbc.M114.599266.
20. Clarke JB. Mechanisms of adverse drug reactions to biologics. Handb Exp Pharmacol (2009) 196:453-74. doi:10.1007/978-3-642-00663-0_16.
21. Pichler WJ. Adverse side-effects to biological agents. Allergy (2006) 61(8):912-20. doi:10.1111/j.1398-9995.2006.01058.x.
22. Sathish JG, Sethu S, Bielsky MC, de Haan L, French NS, Govindappa K, et al. Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov (2013) 12(4):306-24. doi:10.1038/nrd3974.
23. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J (2012) 14(2):296-302. doi:10.1208/s12248-012-9340-y.
24. Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med (2013) 173(15):1416-28. doi:10.1001/jamainternmed.2013.7430.
25. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum (2005) 34(5 Suppl1):19-22. doi:10.1016/j.semarthrit.2005.01.005.
26. Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol (2012) 24(3):306-11. doi:10.1097/BOR.0b013e3283521c4e.
27. Chong BH, Choi PY, Khachigian L, Perdomo J. Drug-induced immune thrombocytopenia. Hematol Oncol Clin North Am (2013) 27:521-40. doi:10.1016/j.hoc.2013.02.003.
28. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA (2011) 305(14):1460-8. doi:10.1001/jama.2011.406.
29. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis (2009) 68(11):1739-45. doi:10.1136/ard.2008.092833.
30. van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie K, Hart MH, de Jong RN, et al. Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem (2014) 289(50):34482-8. doi:10.1074/jbc.M114.615500.
31. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods (2010) 362(1-2):82-8. doi:10.1016/j.jim.2010.09.005.
32. Bendtzen K. Immunogenicity of anti-TNF-α biotherapies: I. Individualized medicine based on immunopharmacological evidence. Front Immunol (2015) 6:152. doi:10.3389/fimmu.2015.00152.
33. Aarskog NK, Marøy T, Myhr KM, Vedeler CA. Antibodies against interferon-beta in multiple sclerosis. J Neuroimmunol (2009) 212(1-2):148-50. doi:10.1016/j.jneuroim.2009.04.012.
34. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet (2003) 362(9391):1184-91. doi:10.1016/S0140-6736(03)14541-2.
35. Scagnolari C, Bellomi F, Turriziani O, Bagnato F, Tomassini V, Lavolpe V, et al. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations. J Interferon Cytokine Res (2002) 22(2):207-13. doi:10.1089/107999002753536176.
36. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med (2002) 346(7):469-75. doi:10.1056/NEJMoa011931.
37. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood (2001) 98(12):3241-8. doi:10.1182/blood.V98.12.3241.
38. Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, DiMichele D, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol (1997) 19(1):23-7. doi:10.1097/00043426-199701000-00003.
39. Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol (2009) 54(2):164-82. doi:10.1016/j.yrtph.2009.03.012.
40. Bellomi F, Scagnolari C, Tomassini V, Gasperini C, Paolillo A, Pozzilli C, et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci (2003) 215(1-2):3-8. doi:10.1016/S0022-510X(03)00173-4.
41. van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization. Ann Rheum Dis (2013) 72:104-9. doi:10.1136/annrheumdis-2012-201445.
42. Sethu S, Govindappa K, Quinn P, Wadhwa M, Stebbings R, Boggild M, et al. Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement. Clin Immunol (2013) 148(2):177-85. doi:10.1016/j.clim.2013.05.008.
43. Stubenrauch K, Kunzel C, Vogel R, Tuerck D, Schick E, Heinrich J. Epitope characterization of the ADA response directed against a targeted immunocytokine. J Pharm Biomed Anal (2015) 114:296-304. doi:10.1016/j.jpba.2015.05.029.
44. Rojas JR, Taylor RP, Cunningham MR, Rutkoski TJ, Vennarini J, Jang H, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther (2005) 313(2):578-85. doi:10.1124/jpet.104.079277.
45. van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink G, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis (2007) 66:253-6. doi:10.1136/ard.2006.057406.
46. Kim MS, Lee SH, Song MY, Yoo TH, Lee BK, Kim YS. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol (2007) 374(5):1374-88. doi:10.1016/j.jmb.2007.10.034.
47. Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nat Rev Immunol (2009) 9(1):15-27. doi:10.1038/nri2454.
48. Kumar S, Singh SK, Wang X, Rup B, Gill D. Coupling of aggregation and immunogenicity in biotherapeutics: T-and B-cell immune epitopes may contain aggregation-prone regions. Pharm Res (2011) 28(5):949-61. doi:10.1007/s11095-011-0414-9.
49. Fehr T, Bachmann MF, Bucher E, Kalinke U, Di Padova FE, Lang AB, et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med (1997) 185(10):1785-92. doi:10.1084/jem.185.10.1785.
50. Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab (1980) 51(4):691-7. doi:10.1210/jcem-51-4-691.
51. Mueller R, Karle A, Vogt A, Kropshofer H, Ross A, Maeder K, et al. Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout. J Pharm Sci (2009) 98(10):3548-61. doi:10.1002/jps.21672.
52. Kromminga A, Schellekens H. Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann N Y Acad Sci (2005) 1050:257-65. doi:10.1196/annals.1313.027.
53. Balázs M, Martin F, Zhou T, Kearney J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity (2002) 17(3):341-52. doi:10.1016/S1074-7613(02)00389-8.
54. De Groot AS, Moise L. Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discov Devel (2007) 10(3):332-40.
55. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol (2007) 28(11):482-90. doi:10.1016/j.it.2007.07.011.
56. Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin Immunol (2013) 149(3):534-55. doi:10.1016/j.clim.2013.09.006.
57. Alvarez HM, So OY, Hsieh S, Shinsky-Bjorde N, Ma H, Song Y, et al. Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice. Drug Metab Dispos (2012) 40(2):360-73. doi:10.1124/dmd.111.042531.
58. Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther (2014) 16(2):R63. doi:10.1186/ar4500.
59. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol (2010) 28(8):863-7. doi:10.1038/nbt.1651.
60. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Théry C, Rescigno M, et al. Fc gamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med (1999) 189(2):371-80. doi:10.1084/jem.189.2.371.
61. Birmingham DJ, Hebert LA. CR1 and CR1-like: the primate immune adherence receptors. Immunol Rev (2001) 180:100-1. doi:10.1034/j.1600-065X.2001.1800109.x.
62. Bajtay Z, Csomor E, Sándor N, Erdei A. Expression and role of Fc-and complement-receptors on human dendritic cells. Immunol Lett (2006) 104(1-2):46-52. doi:10.1016/j.imlet.2005.11.023.
63. Kemper C, Atkinson JP. T-cell regulation: with complements from innate immunity. Nat Rev Immunol (2007) 7(1):9-18. doi:10.1038/nri1994.
64. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself (2010) 1(4):314-22. doi:10.4161/self.1.4.13904.
65. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther (2007) 7(9):1401-13. doi:10.1517/14712598.7.9.1401.
66. van Schouwenburg PA, Krieckaert CL, Nurmohamed M, Hart M, Rispens T, Aarden L, et al. IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol (2012) 32(5):1000-6. doi:10.1007/s10875-012-9705-0.
67. Aalberse RC, van der Gaag R, van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol (1983) 130(2):722-6.
68. Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. Distribution of Th1-and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost (2002) 88(4):568-75.
69. von Wussow P, Jakschies D, Freund M, Deicher H. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy. J Interferon Res (1989) 9(Suppl 1):S25-31.
70. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy (2010) 65(5):657-61. doi:10.1111/j.1398-9995.2009.02280.x.
71. Bindon CI, Hale G, Brüggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med (1988) 168(1):127-42. doi:10.1084/jem.168.1.127.
72. Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol (2011) 11(3):262-8. doi:10.1097/ACI.0b013e3283464bcd.
73. Vultaggio A, Nencini F, Pratesi S, Petroni G, Maggi E, Matucci A. Manifestations of antidrug antibodies response: hypersensitivity and infusion reactions. J Interferon Cytokine Res (2014) 34(12):946-52. doi:10.1089/jir.2012.0139.
74. Jönsson F, Mancardi DA, Zhao W, Kita Y, Iannascoli B, Khun H, et al. Human FcγRIIA induces anaphylactic and allergic reactions. Blood (2012) 119(11):2533-44. doi:10.1182/blood-2011-07-367334.
75. Jönsson F, Mancardi DA, Kita Y, Karasuyama H, Iannascoli B, Van Rooijen N, et al. Mouse and human neutrophils induce anaphylaxis. J Clin Invest (2011) 121(4):1484-96. doi:10.1172/JCI45232.
76. Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with anti-adalimumab antibodies: a case series and cohort study. Arthritis Rheum (2011) 63(4):877-83. doi:10.1002/art.30209.
77. Bendtzen K. Immunogenicity of anti-TNF-α biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. Front Immunol (2015) 6:109. doi:10.3389/fimmu.2015.00109.
78. Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods (2011) 372(1-2):196-203. doi:10.1016/j.jim.2011.07.019.
79. Bourdage JS, Cook CA, Farrington DL, Chain JS, Konrad RJ. An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods (2007) 327(1-2):10-7. doi:10.1016/j.jim.2007.07.004.
80. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol (2008) 20(4):431-5. doi:10.1016/j.coi.2008.06.011.
81. Stubenrauch K, Wessels U, Essig U, Vogel R, Schleypen J. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. J Pharm Biomed Anal (2010) 52:249-54. doi:10.1016/j.jpba.2009.12.029.
82. Pierog P, Krishna M, Yamniuk A, Chauhan A, DeSilva B. Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples. J Immunol Methods (2015) 416:124-36. doi:10.1016/j.jim.2014.11.007.
83. Van Hoeyveld E, Bossuyt X. Evaluation of seven commercial ELISA kits compared with the C1q solid-phase binding RIA for detection of circulating immune complexes. Clin Chem (2000) 46:283.
84. Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol (2013) 56(3):232-9. doi:10.1016/j.molimm.2013.05.221.
85. Angata T. Associations of genetic polymorphisms of Siglecs with human diseases. Glycobiology (2014) 24(9):785-93. doi:10.1093/glycob/cwu043.
86. Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, et al. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the innovative medicines initiative ABIRISK consortium. Clin Exp Immunol (2015) 181(3):385-400. doi:10.1111/cei.12652.
87. Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) (2014) 53(2):213-22. doi:10.1093/rheumatology/ket260.